Tag: Bristol-Myers Squibb Co

Finance

Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE) announced that PROFILE 1014, a phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. Pfizer Inc. (NYSE:PFE) stock performance was 1.13% in last session and finished the day at $32.18. … Continue reading Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis
FB Nasdaq FB Facebook
Finance

Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY), Merck & Co (NYSE:MRK)

US pharma giant Pfizer (NYSE:PFE) has announced detailed results from OPT Compare (A3921080), a Phase III study of tofacitinib (trade name Xeljanz), the first in a new class of treatment, oral Janus kinase (JAK) inhibitors, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Pfizer Inc. (NYSE:PFE) stock performance was -2.14% in last session and … Continue reading Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY), Merck & Co (NYSE:MRK)

Jayne Crisman
FB Nasdaq FB Facebook
Finance

Healthcare Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Galena Biopharma (NASDAQ:GALE)

Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) reported financial results for the fourth quarter and year ended December 31, 2013. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) stock performance was -2.29% in last session and finished the day at $3.42. Traded volume was 7.95 million shares in the last session and the average volume of the stock remained 8.89 million shares. The beta of the stock remained 3.55. Inovio Pharmaceuticals … Continue reading Healthcare Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Galena Biopharma (NASDAQ:GALE)

John Bellich
Finance

Drug manufacturer Most Active: Merck & Co. (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Raptor Pharmaceutical (NASDAQ:RPTP)

Bristol-Myers Squibb Co (NYSE:BMY)’s ipilimumab, or Yervoy as it’s commercially known, was dubbed the skin cancer ‘wonder’ drug by the media when it was licensed for use in the UK in 2011. Bristol-Myers Squibb Co (NYSE:BMY) dropped -0.33 percent to $54.00 Friday on volume of 8.05million shares. The intra-day range of the stock was $53.88 to $54.44. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization … Continue reading Drug manufacturer Most Active: Merck & Co. (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Raptor Pharmaceutical (NASDAQ:RPTP)

Chris Lewis
BioTech

Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Peregrine Pharmaceuticals (NASDAQ:PPHM) is scheduled to be releasing its Q314 earnings data on Friday, March 7th. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was 47.64% in last session and finished the day at $2.82. Traded volume was 36.76million shares in the last session and the average volume of the stock remained 3.12million shares. The beta of the stock remained 1.40. Peregrine Pharmaceuticals (NASDAQ:PPHM) insider ownership is 16%. … Continue reading Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Colin Pettis